Study of XB010 in Subjects With Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze.
- •Stan ogólny pozwalający na codzienne czynności (np. samodzielne poruszanie się).
- •Dobre wyniki badań krwi i prawidłowe działanie narządów.
- •Potwierdzony nowotwór lity, który nie nadaje się do operacji lub rozprzestrzenił się.
- •Możliwość przestrzegania zasad badania i podpisanie zgody na udział.
- •Pacjenci z rakiem płuca (niezwykłkokomórkowym), rakiem piersi (hormonowrażliwym lub potrójnie ujemnym), rakiem głowy i szyi lub rakiem przełyku.
✗ Disqualifies
- •Osoby, które nie spełniają powyższych kryteriów kwalifikacji.
- •Osoby, które uczestniczą w innym badaniu klinicznym.
- •Kobiety w ciąży lub karmiące piersią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (20)
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, United States
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, United States
Georgetown University Medical Center
Washington D.C., United States
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, United States
Winship Cancer Institute
Atlanta, United States
University of Chicago Medical Center
Chicago, United States
Siteman Cancer Center
St Louis, United States
Montefiore Medical Center - Montefiore Medical Park
The Bronx, United States
Carolina BioOncology Institute
Huntersville, United States
Stephenson Cancer Center
Oklahoma City, United States
SCRI Oncology Partners
Nashville, United States
NEXT Austin
Austin, United States
Baylor University Medical Center
Dallas, United States
University of Texas MD Anderson Cancer Center
Houston, United States
Inova Schar Cancer
Fairfax, United States
NEXT Virginia
Fairfax, United States
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Sarah Cannon Research Institute London
London, United Kingdom
University College London Hospitals NHS Foundation Trust
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Trial contact
Exelixis Clinical Trials
Backup or International
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.